Nov 20 2008
National Neurovision Research Institute (NNRI), a research support organization for the Foundation Fighting Blindness and the leading non-government funding source for inherited orphan retinal degeneration research, and Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced a research collaboration whereby NNRI will fully fund preclinical studies to evaluate the potential of novel resolvin therapeutics for eye diseases of the retina that lack current treatments, specifically genetic retinal degenerative diseases and dry age-related macular degeneration (AMD).
Under the agreement, NNRI will fully fund preclinical studies and will also provide access to specialized research facilities and ocular research experts to conduct studies to evaluate the effectiveness of resolvins for specific eye diseases. Resolvyx will provide the company’s proprietary resolvin therapeutics, including RX-10001, RX-10008, and RX-20001, for the research studies. Resolvyx will retain all rights to develop and commercialize these compounds and any discoveries that result from the collaboration.
"Resolvins offer an exciting new approach to effectively treat people affected by retinal degenerative diseases," said Steve Rose, Ph.D., Chief Research Officer, Foundation Fighting Blindness. "These diseases are among the most difficult to treat and represent a significant unmet medical need. Resolvins have the potential to change the lives of patients affected by these devastating conditions which are a major cause of vision loss."
"We are extremely encouraged by the potential for resolvins to treat a number of serious eye diseases, as we have demonstrated that resolvins have a unique ability to naturally inhibit key inflammatory processes, preserve the integrity of eye tissue and promote eye tissue repair," said Per Gjorstrup, M.D., Ph.D., Chief Medical Officer of Resolvyx Pharmaceuticals. "We look forward to working with NNRI to continue to advance our promising ocular compounds to address serious eye diseases for which there are currently no effective treatment options."